Vinko Besic
I completed my PhD at the University of Otago (New Zealand) focusing on insulin signalling before and after gastric bypass surgery, in which I trained as a molecular biologist with some bioinformatics experience. Throughout my PhD I became interested in the relationship between bacteria and their host, and the role of RNA in regulating physiological and pathological processes. In the team of A. Lebreton, I studied the impact of Listeria monocytogenes infection on eukaryotic mRNA translation.
Education
| 2008-2013 | PhD in Molecular Pathology, University of Otago, Wellington, New Zealand. |
| 2007 | Post-graduate Diploma in Medical Laboratory Science (with Distinction), Specializing in Molecular Pathology, University of Otago, Dunedin, New Zealand. |
| 2003-2006 | Bachelor of Medical Laboratory Science, Specializing in Biochemistry and Microbiology, University of Otago, Dunedin, New Zealand. |
Research experience
| Since 2022 | Scientist in the team Bioinformatics and Genomics at the Institute of Environmental Science and Research (ENS), New Zealand |
| 2020-2021 | Post-doctoral position (ESPCI) |
| 2015-2020 | Post-doctoral position (IBENS, Group A. Lebreton) Translational response of human cells to Listeria infection. |
| 2014 | Assistant Research Fellow, Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand. |
| 2013-2014 | Research Officer, Wakefield Biomedical Research Unit, Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand. |
| 2009-2013 | Part-time Medical Laboratory Scientist, Capital and Coast District Health Board, Wellington, New Zealand. |
| 2008-2013 | PhD student, Wakefield Biomedical Research Unit, Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand. Liver molecular mechanisms behind the remission of type 2 diabetes after gastric bypass surgery. |
| 2007 | Post-graduate student in Molecular Pathology, University of Otago, Dunedin, New Zealand. YB1, post translational modifications of p53 and cell fate. |
